COVID-19 (severe/fatal) |
Treatment |
Concomitant medication [Anti-tumor treatment <=14 days before COVID-19 diagnosis vs. Anti-tumor treatment >14 days before COVID-19 diagnosis] |
Hazard ratio: 4.080 (1.090-15.320)
§† |
Zhang
|
|
|
COVID-19 (severe/critical) |
Patient characteristics |
Gender [Male vs. Female] |
Odds ratio: 1.610 (1.250-2.070)
|
Xu
|
|
|
COVID-19 (severe/critical) |
Patient characteristics |
Age [1 year increase vs. Not applicable] |
Weighted Mean Difference: 11.890 (8.630-15.140)
§ |
Xu
|
|
|
SARS COV-2 infection |
Patient characteristics |
Age [40-49 years vs. 20-39 years] |
Odds ratio: 1.010 (0.630-1.620)
† |
Russell
|
|
|
SARS COV-2 infection |
Patient characteristics |
Age [50-59 years vs. 20-39 years] |
Odds ratio: 2.000 (1.370-2.920)
† |
Russell
|
|
|
SARS COV-2 infection |
Patient characteristics |
Age [60-69 years vs. 20-39 years] |
Odds ratio: 2.730 (2.010-3.710)
† |
Russell
|
|
|
SARS COV-2 infection |
Patient characteristics |
Age [70-79 years vs. 20-39 years] |
Odds ratio: 3.450 (2.560-4.640)
† |
Russell
|
|
|
SARS COV-2 infection |
Patient characteristics |
Age [80-89 years vs. 20-39 years] |
Odds ratio: 3.830 (2.560-5.730)
† |
Russell
|
|
|
Developing COVID-19 after contamination |
Patient characteristics |
Age [40-49 years vs. 20-39 years] |
Odds ratio: 0.460 (0.160-1.330)
† |
Russell
|
|
|
Developing COVID-19 after contamination |
Patient characteristics |
Age [50-59 years vs. 20-39 years] |
Odds ratio: 0.170 (0.070-0.410)
† |
Russell
|
|
|
Developing COVID-19 after contamination |
Patient characteristics |
Age [60-69 years vs. 20-39 years] |
Odds ratio: 0.140 (0.070-0.300)
† |
Russell
|
|
|
Developing COVID-19 after contamination |
Patient characteristics |
Age [70-79 years vs. 20-39 years] |
Odds ratio: 0.130 (0.060-0.270)
† |
Russell
|
|
|
Developing COVID-19 after contamination |
Patient characteristics |
Age [80-89 years vs. 20-39 years] |
Odds ratio: 0.220 (0.090-0.530)
† |
Russell
|
|
|
COVID-19 (any condition) |
Patient characteristics |
Age [40-49 years vs. 20-39 years] |
Odds ratio: 0.840 (0.490-1.440)
† |
Russell
|
|
|
COVID-19 (any condition) |
Patient characteristics |
Age [50-59 years vs. 20-39 years] |
Odds ratio: 1.050 (0.650-1.690)
† |
Russell
|
|
|
COVID-19 (any condition) |
Patient characteristics |
Age [60-69 years vs. 20-39 years] |
Odds ratio: 1.250 (0.860-1.800)
† |
Russell
|
|
|
COVID-19 (any condition) |
Patient characteristics |
Age [70-79 years vs. 20-39 years] |
Odds ratio: 1.440 (1.010-2.040)
† |
Russell
|
|
|
COVID-19 (any condition) |
Patient characteristics |
Age [80-89 years vs. 20-39 years] |
Odds ratio: 2.160 (1.330-3.490)
† |
Russell
|
|
|
Asymptomatic SARS COV-2 |
Patient characteristics |
Age [40-49 years vs. 20-39 years] |
Odds ratio: 1.880 (0.730-4.800)
† |
Russell
|
|
|
Asymptomatic SARS COV-2 |
Patient characteristics |
Age [50-59 years vs. 20-39 years] |
Odds ratio: 6.460 (3.130-13.320)
† |
Russell
|
|
|
Asymptomatic SARS COV-2 |
Patient characteristics |
Age [60-69 years vs. 20-39 years] |
Odds ratio: 9.400 (4.870-18.140)
† |
Russell
|
|
|
Asymptomatic SARS COV-2 |
Patient characteristics |
Age [70-79 years vs. 20-39 years] |
Odds ratio: 12.140 (6.340-23.230)
† |
Russell
|
|
|
Asymptomatic SARS COV-2 |
Patient characteristics |
Age [80-89 years vs. 20-39 years] |
Odds ratio: 10.010 (4.730-21.200)
† |
Russell
|
|
|
COVID-19 (severe/fatal) |
Comorbidities |
Diabetes [Present vs. Not present] |
Hazard ratio: 2.340 (1.350-4.050)
† |
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Neutrophils [Abnormal at admission vs. Normal] |
Hazard ratio: 1.140 (1.090-1.190)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Lymphocytes [Abnormal at admission vs. Normal] |
Hazard ratio: 0.370 (0.210-0.630)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
CD3 [Abnormal at admission vs. Normal] |
Hazard ratio: 0.830 (0.720-0.960)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
CD4 [Abnormal at admission vs. Normal] |
Hazard ratio: 0.740 (0.590-0.930)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
CD8 [Abnormal at admission vs. Normal] |
Hazard ratio: 0.740 (0.530-1.040)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Total bilirubin [Abnormal at admission vs. Normal] |
Hazard ratio: 1.050 (1.020-1.080)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
AST [Abnormal at admission vs. Normal] |
Hazard ratio: 1.020 (1.010-1.030)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
ALT [Abnormal at admission vs. Normal] |
Hazard ratio: 1.000 (0.999-1.010)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Albumin [Abnormal at admission vs. Normal] |
Hazard ratio: 0.490 (0.370-0.660)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Globulin [Abnormal at admission vs. Normal] |
Hazard ratio: 2.320 (1.450-3.710)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Prealbumin [Abnormal at admission vs. Normal] |
Hazard ratio: 0.990 (0.980-0.990)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Urea [Abnormal at admission vs. Normal] |
Hazard ratio: 1.130 (1.090-1.180)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Creatinine [Abnormal at admission vs. Normal] |
Hazard ratio: 1.050 (1.010-1.100)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Glucose [Abnormal at admission vs. Normal] |
Hazard ratio: 1.130 (1.080-1.190)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
CK-MB [Abnormal at admission vs. Normal] |
Hazard ratio: 1.010 (1.000-1.020)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Cholinesterase [Abnormal at admission vs. Normal] |
Hazard ratio: 0.810 (0.730-0.900)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Cystatin C [Abnormal at admission vs. Normal] |
Hazard ratio: 1.690 (1.310-2.190)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
LDH [Abnormal at admission vs. Normal] |
Hazard ratio: 1.610 (1.440-1.790)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
a-HBDH [Abnormal at admission vs. Normal] |
Hazard ratio: 1.740 (1.520-1.990)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
LDL [Abnormal at admission vs. Normal] |
Hazard ratio: 0.630 (0.440-0.880)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
hs-CRP [Abnormal at admission vs. Normal] |
Hazard ratio: 4.810 (1.520-15.270)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
IL-6 [Abnormal at admission vs. Normal] |
Hazard ratio: 1.020 (1.000-1.050)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Serum ferritin [Abnormal at admission vs. Normal] |
Hazard ratio: 3.530 (1.520-8.160)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
PT [Abnormal at admission vs. Normal] |
Hazard ratio: 1.560 (1.320-1.830)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
APTT [Abnormal at admission vs. Normal] |
Hazard ratio: 0.970 (0.940-1.010)
|
Wu
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
D-dimer [Abnormal at admission vs. Normal] |
Hazard ratio: 1.030 (1.010-1.040)
|
Wu
|
|
|